bioMerieux (OTCMKTS:BMXMF) Reaches New 52-Week Low – Should You Sell?

bioMerieux (OTCMKTS:BMXMF)’s stock price reached a new 52-week low during trading on Wednesday . The company traded as low as $109.61 and last traded at $109.61, with a volume of 60 shares changing hands. The stock had previously closed at $110.62.

Wall Street Analyst Weigh In

Separately, BNP Paribas Exane cut shares of bioMerieux to a “neutral” rating in a research report on Wednesday, January 28th. Two equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, bioMerieux presently has a consensus rating of “Hold”.

bioMerieux Trading Down 0.4%

The company has a debt-to-equity ratio of 0.08, a current ratio of 2.27 and a quick ratio of 1.30. The stock’s 50-day moving average price is $121.17 and its two-hundred day moving average price is $128.41.

About bioMerieux

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.